Mentorship and Research in Bipolar and Substance Use Disorders

双相情感障碍和药物滥用障碍的指导和研究

• 批准号: 10740403
• 负责人: James Joseph Prisciandaro
• 金额: $ 21.5万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10740403
• 关键词: Academic Medical Centers; Area; Award; Behavioral Sciences; Bioinformatics; Biological Psychiatry; Biometry; Blood specimen; Brain; Clinical; Clinical Investigator; Data; Development; Diagnosis; Employment; Exposure to; Faculty; Funding; Future Generations; Genomics; Glutamates; Goals; Grant; Image; Individual; Investigation; Licensing; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measurable; Medical; Mentors; Mentorship; Methodology; Methods; Mid-Career Clinical Scientist Award (K24); Monitor; National Institute on Alcohol Abuse and Alcoholism; Participant; Pharmaceutical Preparations; Phenotype; Postdoctoral Fellow; Productivity; Protons; Psychiatry; Psychologist; Research; Research Methodology; Resources; Science; Scientist; Source; South Carolina; Substance Use Disorder; Time; Training; United States National Institutes of Health; Universities; Wages; Work; addiction; alcohol cue; alcohol response; alcohol use disorder; biomedical imaging; career; cost; design; experience; gabapentin; gamma-Aminobutyric Acid; genetic variant; genomic variation; imaging study; improved; meetings; member; mid-career faculty; multimodality; neurobehavioral; neurochemistry; participant enrollment; patient oriented research; pharmacologic; programs; psychiatric genomics; psychogenetics; recruit; research study; skills; statistics; success

Dr. James J. Prisciandaro is a licensed Clinical Psychologist, Associate Professor in the Addiction Sciences Division of the Department of Psychiatry & Behavioral Sciences at the Medical University of South Carolina (MUSC), who is committed to making a measurable impact on our understanding and ability to treat individuals with bipolar (BD) and/or substance use disorders (SUD) through his program of patient-oriented research (POR). Dr. Prisciandaro has served as PI, Co-PI, or Co-I on 12 NIH-funded grant awards since joining MUSC in 2009, but his success in designing and executing NIH-funded research studies has come at a significant cost: his efforts to mentor new clinical investigators have been greatly limited by his employment within an academic medical center that is not able to provide faculty with protected time for mentoring or professional development. As a result of this lack of support, Dr. Prisciandaro has had to greatly limit the number of new clinical investigators that he has been able to mentor, and he has not been able to expand his methodological skillset since completing his K23 training 5-years ago. The proposed K24 award would allow Dr. Prisciandaro to fulfil his career goals by providing him with the protected time and supplementary funding needed to comprehensively train significantly more new clinical investigators and to develop and expand his methodological skills in MRI and statistics to include genomics. Towards this end, Dr. Prisciandaro has recruited several consultants and collaborators to help him create, execute, and monitor a comprehensive training plan, including longstanding collaborators within his fields of expertise (Drs. Richard Edden [MRI] and Michaela Hoffman [biostatistics]) along with three new consultants/collaborators, Drs. Ananda Amstadter (psychiatric genomics), Stefano Berto (genomics and bioinformatics), and Zhewu Wang (psychiatric genetics). With their guidance, Dr. Prisciandaro has proposed a research strategy to apply cutting-edge genomics methods to blood samples that he has collected from every participant enrolled in each of his NIH-funded studies to date, starting with those from his K23 study; a 2*2 factorial (BD*alcohol use disorder [AUD]), multimodal-MRI investigation of neurochemical (i.e., GABA and glutamate levels) and neurobehavioral overlap (i.e., activation to alcohol cues and response inhibition) between BD and AUD. Dr. Prisciandaro will devote the remainder of his effort to his current NIH-funded program of POR, focused on pharmacologically-manipulating intermediate MRI phenotypes of BD and/or SUD, which is tightly aligned with his career goals and a rich source for mentee training and productivity. As these pharmaco-imaging studies complete participant enrollment, Dr. Prisciandaro and his consultants/collaborators will apply to their data the proposed genomics methods, extended to include genetic variants underlying the mechanisms of action of the medications under investigation (e.g., gabapentin). He will involve mentees in all aspects of his POR, including all proposed genomics research. Together, these combined efforts will significantly advance both Dr. Prisciandaro's POR career as well as our understanding of and ability to treat individuals with BD+SUD.

James J. Prisciandaro博士是持牌临床心理学家，成瘾科学副教授 南卡罗来纳州医科大学精神病学和行为科学系 （MUSC），致力于对我们的理解和对待个人的能力产生可衡量的影响 通过双极性（BD）和/或药物使用障碍（SUD）通过其面向患者的研究计划（POR）。 自2009年加入MUSC以来 但是他在设计和执行NIH资助的研究方面的成功取得了巨大的代价：他的 指导新的临床研究人员的努力受到学术中的工作的极大限制 无法为教师提供指导或专业发展的受保护时间的医疗中心。 由于缺乏支持，Prisciandaro博士不得不大大限制了新的临床研究人员的数量 他已经能够指导，并且自完成以来，他一直无法扩展他的方法论技巧 他的K23培训5年前。拟议的K24奖将使Prisciandaro博士能够实现他的职业目标 为他提供受保护的时间和补充资金，以全面培训 更多新的临床研究人员，并将其在MRI和统计数据中发展和扩展他的方法论技巧 包括基因组学。为此，Prisciandaro博士招募了几位顾问和合作者来帮助 他创建，执行和监控全面的培训计划，包括他的长期合作者 专业知识领域（理查德·埃德登（MRI）博士和迈克尔·霍夫曼（Michaela Hoffman）[生物统计学]）以及三个新的 顾问/合作者，博士。 Ananda Amstadter（精神病基因组学），Stefano Berto（基因组学和 生物信息学）和Zhewu Wang（精神遗传学）。在他们的指导下，Prisciandaro博士提出了 研究策略将最先进的基因组学方法应用于他从每个人那里收集的血液样本 迄今为止，参与者参加了他的NIH资助的每项研究，从他的K23研究中开始。 A 2*2 阶乘（BD*酒精使用障碍[AUD]），神经化学的多模式-MRI研究（即GABA和GABA和 谷氨酸水平）和神经行为重叠（即酒精提示和抑制作用） BD和AUD。 Prisciandaro博士将致力于他目前由NIH资助的POR计划， 专注于BD和/或SUD的药理操纵中间MRI表型，这是紧密的 与他的职业目标保持一致，也是指导培训和生产力的丰富来源。作为这些药房成像 研究完成了参与者的入学，Prisciandaro博士和他的顾问/合作者将适用于他们的数据 提出的基因组学方法扩展到包括遗传变异的基础，该变异的作用机理的基础 正在研究的药物（例如，加巴喷丁）。他将使受训者参与他的POR的各个方面， 包括所有提出的基因组学研究。这些综合努力将大大推动博士。 Prisciandaro的职业生涯以及我们对BD+SUD的个人的理解和能力。